Literature DB >> 28468011

Overcoming CD8+ T-Cell Exhaustion in Viral Hepatitis: Lessons from the Mouse Model and Clinical Perspectives.

Dominik Wieland1, Maike Hofmann, Robert Thimme.   

Abstract

About 500 million people all over the world are chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) and are thus at high risk of developing liver fibrosis, cirrhosis or hepatocellular carcinoma. While in adults about 90% of acutely HBV-infected patients clear the virus, only 30% of acute HCV infections clear spontaneously. Several mechanisms contribute to the failure in viral clearance. The main factors responsible for the chronification of HBV and HCV infection are, on the one hand, viral escape mutations leading to lack of recognition by antiviral immune cells and, on the other hand, loss of antiviral effector functions of virus-specific CD8+ T cells, called T-cell exhaustion. This review focuses on the latter highlighting current knowledge about the heterogeneity of exhausted CD8+ T cells and the potential for re-invigoration of exhausted T-cell populations during chronic viral hepatitis. Although direct-acting antivirals successfully clear chronic HCV infection, there is still the need for a prophylactic vaccine to prevent primary infection. Moreover, a therapeutic strategy eliminating HBV infection still does not exist. A better understanding of T-cell exhaustion and the potential for functional recovery will help to develop new immunotherapeutic approaches for chronic viral hepatitis.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Checkpoint inhibitors; T-cell exhaustion; T-cell restoration

Mesh:

Substances:

Year:  2017        PMID: 28468011     DOI: 10.1159/000456584

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  16 in total

Review 1.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

Review 2.  Medicinal Plants and Isolated Molecules Demonstrating Immunomodulation Activity as Potential Alternative Therapies for Viral Diseases Including COVID-19.

Authors:  Hassan A Alhazmi; Asim Najmi; Sadique A Javed; Shahnaz Sultana; Mohammed Al Bratty; Hafiz A Makeen; Abdulkarim M Meraya; Waquar Ahsan; Syam Mohan; Manal M E Taha; Asaad Khalid
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

3.  Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.

Authors:  Xue Shao; Jingting Ma; Shengnan Jia; Lanlan Yang; Wudong Wang; Zhenjing Jin
Journal:  Front Cell Infect Microbiol       Date:  2017-11-13       Impact factor: 5.293

4.  Complement System as a Target for Therapies to Control Liver Regeneration/Damage in Acute Liver Failure Induced by Viral Hepatitis.

Authors:  Juliana Gil Melgaço; Carlos Eduardo Veloso; Lúcio Filgueiras Pacheco-Moreira; Claudia Lamarca Vitral; Marcelo Alves Pinto
Journal:  J Immunol Res       Date:  2018-10-08       Impact factor: 4.818

Review 5.  Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.

Authors:  Peter A Revill; Capucine Penicaud; Christian Brechot; Fabien Zoulim
Journal:  Genes (Basel)       Date:  2019-04-01       Impact factor: 4.096

6.  Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells.

Authors:  Jodi Wong; Stephen Yiu Chuen Choi; Rongrong Liu; Eddie Xu; James Killam; Peter W Gout; Yuzhuo Wang
Journal:  Front Cell Infect Microbiol       Date:  2019-02-12       Impact factor: 5.293

Review 7.  CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.

Authors:  Yan Yan; Renfang Chen; Xu Wang; Kai Hu; Lihua Huang; Mengji Lu; Qinxue Hu
Journal:  Front Cell Dev Biol       Date:  2019-10-01

Review 8.  Current impact of viral hepatitis on liver cancer development: The challenge remains.

Authors:  Ângelo Zambam de Mattos; Jose D Debes; Andre Boonstra; Ju-Dong Yang; Domingo C Balderramo; Giovana D P Sartori; Angelo Alves de Mattos
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

9.  Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.

Authors:  Fang Li; Na Li; Jiao Sang; Xiude Fan; Huan Deng; Xiaoge Zhang; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

10.  Alphavirus-based hepatitis C virus therapeutic vaccines: can universal helper epitopes enhance HCV-specific cytotoxic T lymphocyte responses?

Authors:  Georgia Koutsoumpli; Peng Peng Ip; Ilona Schepel; Baukje Nynke Hoogeboom; Annemarie Boerma; Toos Daemen
Journal:  Ther Adv Vaccines Immunother       Date:  2019-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.